KindredBio Schedules Release of 2014 Second Quarter Financial Results and Provides Timeline for Release of CereKin Pivotal Study Data

SAN FRANCISCO, California. (Aug 6, 2014) – Kindred Biosciences, Inc. (KindredBio, NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, announced the date for release of its 2014 second quarter financial results and provided the timeline for the release of topline data from its multi-center, pivotal clinical trial of CereKin™ […]

Kindred Biosciences Announces First Quarter 2014 Financial Results and Completion of Enrollment in CereKin Pivotal Study

San Francisco, CA (May 12, 2014) Kindred Biosciences, Inc. (NASDAQ: KIN) today announced financial results for the quarter ended March 31, 2014. In addition, KindredBio announced that it has completed enrollment in KB010, its pivotal study for CereKinTM (diacerein).

KindredBio to Announce First Quarter 2014 Financial Results on Monday, May 12th

Company to Hold Conference Call and Webcast at 4:30 p.m. Eastern Time that Day SAN FRANCISCO, California. (May 6, 2014) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, announced today that it will release its first quarter 2014 financial results on May 12, 2014 after […]

KindredBio Announces Closing of Public Offering and Exercise of Over-Allotment Option

SAN FRANCISCO, California. (April 8, 2014) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced the closing of its public offering of 3,450,000 shares of its common stock, including 450,000 shares sold pursuant to the exercise in full by the underwriters of their over-allotment […]

Kindred Bio Announces Pricing of Public Offering

SAN FRANCISCO, California. (April 3, 2014) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced the pricing of its public offering of 3,000,000 shares of its common stock at a public offering price of $18.00 per share, for a total offering amount of $54,000,000 […]